Italia markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,70-0,02 (-0,19%)
Alla chiusura: 04:00PM EST
10,45 -0,25 (-2,34%)
Dopo ore: 06:55PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente10,72
Aperto10,83
Denaro10,45 x 1000
Lettera10,98 x 1100
Min-Max giorno10,64 - 10,92
Intervallo di 52 settimane6,54 - 21,50
Volume287.639
Media Volume283.296
Capitalizzazione455,569M
Beta (5 anni mensile)2,29
Rapporto PE (ttm)N/D
EPS (ttm)-1,94
Prossima data utili03 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A44,64
  • GlobeNewswire

    COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

    12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to acc

  • GlobeNewswire

    COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

    LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be acc

  • GlobeNewswire

    COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

    LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data published in The New England Journal of MedicineCash position at 30 September 2022 of $173.1 millionConference call today at 8:00am ET (12:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health